Compare Cytokinetics Inc (CYTK) vs AT&T Inc. (T) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs AT&T Inc. — how do they compare? Cytokinetics Inc trades at $62.72 (market cap $8.62B), while AT&T Inc. trades at $22.05 (market cap $170.42B). The key difference: AT&T Inc. is far larger — about 19.8× Cytokinetics Inc's market cap, and AT&T Inc. pays a 4.46% dividend while Cytokinetics Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and AT&T Inc. for 118 Days on average.
| CYTK | T | |
|---|---|---|
Market Cap | $8.62B | $170.42B |
Volume | 2,594,626 | 50,780,036 |
Sector | Health | Media |
52-Week High | $87.26 | $29.10 |
52-Week Low | $54.76 | $20.49 |
Typical Hold Time | 19 Days | 118 Days |
Enterprise Value | $8.72B | $315.74B |
Dividend Yield | — | 4.46% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $62.66, up 2.52% on the day, amid a bearish technical signal from moving averages but with oversold RSI readings. The company reported a net loss of -$784.96M on $88.04M revenue in 2025, with a negative net income margin of -1,321.12%, reflecting high R&D and commercialization costs. Recent news highlights clinical progress, including positive Phase 3 results for aficamten in non-obstructive HCM and upcoming presentations at the HFSA Annual Scientific Meeting 2026.
The investment case hinges on successful drug commercialization and pipeline execution, with a consensus analyst price target of $112.60 implying significant upside. However, persistent losses, high cash burn, and competitive pressures in the cardiovascular drug market present substantial risks. Near-term catalysts include the Q3 2026 earnings report and regulatory submissions for aficamten.
AT&T (T) trades at $22.105, down 9.68% in the last session, reflecting market concerns despite strong fundamentals. The stock shows solid profitability with 16.94% net margin and attractive valuation at 8.21 P/E. Recent earnings beats and a $3 billion fiber deal with Corning highlight growth initiatives, while technical indicators show mixed signals with RSI at neutral levels.
The outlook remains balanced with analyst consensus at $27.50 target suggesting 24% upside, supported by fiber expansion and wireless growth. Key risks include heavy debt load at $118.44 billion and competitive pressures. The 4% dividend yield provides income support, but investors should monitor execution on debt reduction and revenue trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About AT&T Inc.
AT&T Inc. is a communications holding company. The Company, through its subsidiaries and affiliates, provides local and long-distance phone service, wireless and data communications, Internet access and messaging, IP-based and satellite television, security services, telecommunications equipment, and directory advertising and publishing.
Read more on T →
